TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03686488 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions

DRUG: TAS 102
DRUG: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]

Sponsor

H. Lee Moffitt Cancer Center and Research Institute